This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Sales Improve at Rite Aid

Rite Aid (RAD) is slowly putting its turnaround back on track.

The company, the nation's third-largest drugstore chain, said Thursday that its losses were less than anticipated in the fourth quarter as sales continued to pick up. The results offered the latest evidence of increasing spending by consumers as the economy makes its way back from a brief recession.

Thursday's news was perhaps most notable because a drugstore chain other than Walgreen (WAG) had good news for Wall Street. Walgreen, the clear industry leader, has benefited lately from problems at virtually all its rivals, including CVS (CVS), which has had to take hefty charges to close stores, and J.C. Penney's (JCP) Eckerd chain, which has been beset by lawsuits.


For the fourth quarter ended March 2, Rite Aid lost $257.9 million, or 52 cents a share, compared with a net loss of $362.1 million, or $1.07 a share, in the same period last year.

Rite Aid said its loss, excluding charges, was 8 cents a share, compared with the consensus expectation of a loss of 11 cents, according to Thomson Financial/First Call. Revenue in the quarter was $4 billion, vs. revenue of $4.1 billion in last year's fourth quarter, which included one extra week.

Shares were off 18 cents at $3.74 in recent trading, or about double their 52-week low reached in January.

"Sales growth improved month to month during the period, and this positive momentum has continued into our new fiscal year," said Mary Sammons, Rite Aid's president and chief operating officer, in a statement.

The company's cash flow, or earnings before interest, taxes, depreciation and amortization, was also better than expected at $143.5 million, or 3.6% of sales. This number is closely watched by Rite Aid investors and analysts that follow the company because of its history of liquidity problems and accounting irregularities. The company has faced civil and criminal inquiries stemming from allegations it manipulated earnings in 1997, 1998 and 1999.

Rite Aid, which is based in Camp Hill, Pa., and operates about 3,500 stores, certainly had a more pleasant message for Wall Street Thursday than it did earlier this year when the company reported the third quarter. At that time, Rite Aid said its loses were much larger than anticipated and gave cash flow projections that disappointed.

Embracing Risk

During the quarter, same-store sales grew 8.1% compared to a year ago, mainly because of strong prescription drug sales. Sales for front-end items -- the general merchandise goods, such as snacks and stationery -- increased 3.6%. The company said it expects same-store sales to jump 8% to 9% in the first quarter.

Based on the monthly sales data released during the quarter, some analysts had been expecting a strong quarter and began recommending the stock. For example, Neil Currie, of UBS Warburg, recently upgraded to buy from hold. "While we still consider Walgreen to be, by far, the best investment opportunity in the drug retail sector, those willing to embrace more risk may wish to add Rite Aid to their portfolio," he wrote in a recent report. (His firm does not have a banking relationship with the company.)

They also may wish to add Duane Reade (DRD), say some analysts. The New York-centric drugstore chain also posted a good quarter Thursday. Its earnings came in a penny above consensus estimates, but more importantly, the company said earnings could fall above expectations for the second quarter and full year. As a result, Merrill Lynch analyst Monica Aggarwal boosted her rating to strong buy. (Merrill has had a banking relationship with Duane Reade.) Shares were up 50 cents at $33.36.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs